Skip to main content
. Author manuscript; available in PMC: 2017 Jan 15.
Published in final edited form as: Clin Cancer Res. 2015 Aug 25;22(2):374–382. doi: 10.1158/1078-0432.CCR-15-1162

Figure 2. BRAF gene amplification is associated with somatic mutations and worse clinical outcomes.

Figure 2

Kaplan-Meier curves of progression free survival (PFS) (A) and overall survival (OS) (B) based on BRAF gene copy number status, diploid versus copy gain. Median PFS for BRAF diploid and copy gain, 6.3 (95% CI: 3.0, 8.8) months and 3.9 (95% CI: 2.6, 5.3) months (P=0.023), respectively (A). Median OS for BRAF diploid and copy gain, 11.0 (95% CI: 8.8, 18.4) months and 8.5 (95% CI: 7.3, 10.4) months (P=0.046), respectively (B).